Press Release

Feb, 28 2024

Addressing Palmoplantar Pustulosis: Unveiling Severity Factors and Innovative Treatments in the Market

The palmoplantar pustulosis (PPP) market addresses varying severity levels, classified as "mild-moderate" and "moderate-severe." Diagnosis involves laboratory tests and skin biopsies to confirm the condition. Treatment options include emollients to soothe and moisturize affected areas, topical steroids to reduce inflammation, coal tar products for symptom relief, and phototherapy, which uses UV light to manage symptoms. This comprehensive approach provides therapeutic solutions for PPP patients, considering the severity of their condition and enabling personalized care.

Access Full Report @

Data Bridge Market Research analyses that the Europe Palmoplantar Pustulosis (PPP) Market value, which was USD 105.5 million in 2022, is expected to reach the value of USD 155.9 million by 2030, at a CAGR of 5.0% during the forecast period 2023-2030. The increasing incidence of palmoplantar pustulosis (PPP) drives the market by spurring demand for diagnostic tools and treatment options, addressing the growing need to manage this condition effectively and improve patients' quality of life.

Key Findings of the Study

Europe Palmoplantar Pustulosis Market

Aging population is expected to drive the market's growth rate

The aging global population significantly drives the palmoplantar pustulosis (PPP) market. As individuals age, there is a greater susceptibility to various skin disorders, including PPP. This demographic shift increases the likelihood of PPP occurrence, expanding the market's potential. Healthcare providers and pharmaceutical companies are compelled to address the specific needs of this aging population, driving research and the development of treatments tailored to PPP and other age-related skin conditions.

Report Scope and Market Segmentation

Report Metric


Forecast Period

2023 to 2030

Base Year


Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Disease Type (Type A and Type B), Severity (Mild-Moderate and Moderate-Severe), Type (Diagnosis and Treatment), Population Type (Children and Adults), Route Of Administration (Oral, Topical and Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

Market Players Covered

Novartis AG (Switzerland), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.K.), Merck & Co., Inc. (U.S.), Amgen inc. (U.S.), AnGes, Inc. (Japan), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Perrigo Company plc (Ireland), WOCKHARDT (India), Bausch Health Companies Inc. (Canada), Viatris Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Xiromed (U.S.) and Encube Ethicals Private Limited (U.S.)

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The Europe palmoplantar pustulosis (PPP) market is segmented on the basis of disease type, severity, diagnosis, treatment, population type, route of administration, end user, and distribution channel.

  • On the basis of disease type, the Europe palmoplantar pustulosis (PPP) market is segmented into type A and type B.
  • On the basis of severity, the Europe palmoplantar pustulosis (PPP) market is segmented into mild-moderate and moderate-severe.
  • On the basis of diagnosis, the Europe palmoplantar pustulosis (PPP) market is segmented into laboratory tests, and skin biopsy.
  • On the basis of treatment, the Europe palmoplantar pustulosis (PPP) market is segmented into emollients, topical steroids, coal tar, and phototherapy.
  • On the basis of population type, the Europe palmoplantar pustulosis (PPP) market is segmented into children and adults.
  • On the basis of route of administration, the Europe palmoplantar pustulosis (PPP) market is segmented into oral, topical, and parenteral.
  • On the basis of end user, the Europe palmoplantar pustulosis (PPP) market is segmented into hospitals, homecare, specialty clinics, and others.
  • On the basis of distribution channel, the Europe palmoplantar pustulosis (PPP) market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy.

Major Players

Data Bridge Market Research recognizes the following companies as the Europe palmoplantar pustulosis (PPP) market players in Europe palmoplantar pustulosis (PPP) market are Novartis AG (Switzerland), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.K.), Merck & Co., Inc. (U.S.).

Europe Palmoplantar Pustulosis (PPP) Market

Market Developments

  • In June 2022, Aristea Therapeutics Inc., a clinical-stage immunology company focused on advancing therapeutic solutions for severe inflammatory diseases, reported the initiation of the Open-Label Extension (OLE) phase in their Phase 2b trial of RIST4721 for the treatment of palmoplantar pustulosis (PPP), a rare skin condition. They administered the first dose to a subject as part of this trial.
  • In April 2021, Bristol-Myers Squibb revealed significant outcomes from two pivotal Phase 3 clinical trials evaluating deucravacitinib, an orally administered selective tyrosine kinase 2 (TYK2) inhibitor. These trials aimed to assess the drug's effectiveness in treating patients with moderate to severe plaque psoriasis, a common autoimmune skin disorder. The results highlighted deucravacitinib's potential as a promising treatment option for this condition, signifying a breakthrough in psoriasis management.
  • In October 2020, UCB, a leading global biopharmaceutical company, shared new research findings at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam. The data presented focused on the investigational IL-17A and IL-17F inhibitor, bimekizumab, and the TNF inhibitor, CIMZIA (certolizumab pegol), showcasing their efficacy in treating patients with moderate-to-severe plaque psoriasis. This presentation highlighted the potential of these treatments to address this challenging dermatological condition.
  • In February 2020, Eli Lilly & Company acquired Dermira Inc., a prominent dermatology medicine developer, in a deal valued at USD 1.1 billion. This acquisition significantly expanded Eli Lilly's dermatology drug portfolio, allowing the company to diversify its offerings and strengthen its presence in the dermatological pharmaceutical market. It marked a strategic move to address the growing demand for dermatology treatments and innovation in this field.

For more detailed information about the Europe palmoplantar pustulosis (PPP) market report, click here –

Client Testimonials